HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced that a peer-reviewed article in JACC: Advances demonstrated that a risk prediction algorithm incorporating the credit card-sized HeartBeam ECG device can accurately identify heart attack risk in patients presenting with chest pain. This proof-of-concept study evaluated 184 patients and found that the algorithm achieved an “area under the curve” (AUC) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms, rising to 92.9% when a personal, symptom-free baseline ECG was available for comparison. The company said the results support heart attack detection as a future indication for the HeartBeam System and advance its broader clinical program.
The HeartBeam System is designed to collect ECG signals in 3D from three non-coplanar directions and synthesize them into a 12-lead ECG, enabling portable cardiac monitoring. The device received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to its technology.
This study underscores the potential of portable ECG technology to improve early detection of heart attacks, which could significantly impact patient outcomes by enabling timely intervention. The ability to use a personal baseline ECG enhances accuracy, suggesting that routine baseline recordings could become standard practice. For more details, the full press release is available at https://ibn.fm/ainxV. For the latest news and updates on BEAT, visit the company’s newsroom at https://ibn.fm/BEAT.
